Abcam & Cancer Research UK join forces to accelerate cancer research

By Akshay Kedari  | Date: 2020-07-09

Abcam & Cancer Research UK join forces to accelerate cancer research

Cancer Research UK, one of the world's biggest independent funder of cancer research, has recently joined forces with Abcam plc, a leading developer of life science tools and reagents, to commercialize and develop novel custom antibodies to strengthen cancer research.

According to the terms of this partnership, Abcam would create custom protein-based reagents to targets that are recognized by researchers at Cancer Research UK. These antibodies would support the ongoing research and progress the understanding of cancer biology. Moreover, it would potentially be the basis for novel therapies as well as help generate new diagnostic tools.

Upon request, Abcam would deliver unique antibodies created during the terms of the agreement to researchers funded by Cancer Research UK for a pre-determined span of exclusivity in correspondence to that antibody. 

Meanwhile, Abcam’s co-location in key technology spots throughout the world and global supply capability would allow these innovative reagents to be easily available across wider diagnostic and research development community.

Speaking on the move, Tony Hickson, CBO, Cancer Research UK, said that the company is thrilled to collaborate with Abcam to develop tools that scientists require to help advance their understanding of cancer and to extend its access to biological reagents.

Additionally, Abcam’s “end-to-end” expertise and antibody development capabilities would support works of numerous researchers with antibody reagents that could be utilized from the initial stages of R&D right to the clinical trials.

As for Dr. John Baker, SVP of Product Portfolio Innovation, Abcam, the company is delighted to partner with Cancer Research UK to strengthen research by scientist and offer them easy access to validated and specific reagents, thereby helping them attain future breakthrough quickly.

Prior to this news, Abcam had made headlines when it announced that it has purchased assets of oncology product portfolio and gene editing platform from Applied StemCell, Inc. (ASC) for life science diagnostic and research markets. 
 

Source credit: https://www.abcam.com/index.html?pageconfig=news&rid=17091

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Interfor Corporation acquires 100% equity interest in Chaleur Forest Products

Interfor Corporation acquires 100% equity interest in Chaleur Forest Products

By Akshay Kedari

Following this funding, Interfor's long-term debt will hold a weighted average interest of 5.30% Interfor registered a Net Debt to the Invested Capital ratio of nearly 10% as of October 31, 2022 Interfor Corporation, one of the world...

ESR's ARA and Export-Import Bank of China partner in a deal worth US$1B

ESR's ARA and Export-Import Bank of China partner in a deal worth US$1B

By Akshay Kedari

Leading real estate services and investment company, ESR Group Limited, has recently announced that its exclusively-owned subsidiary, ARA and the Export-Import Bank of China have inked a breakthrough collaboration in a deal worth USD 1 billion infras...

Circularise nabs $11M to bring circular economy to industrial supply chains

Circularise nabs $11M to bring circular economy to industrial supply chains

By Akshay Kedari

Leading software platform, Circularise recently announced that it has raised $11.3 million (€11 million) in funding as part of its Series A round in a bid to advance its mission to bring a circular economy to industrial supply chains. The fun...

Sebi approves Adani Group’s proposal for additional 26% stake in NDTV

Sebi approves Adani Group’s proposal for additional 26% stake in NDTV

By Akshay Kedari

Adani Group, an Indian conglomerate, recently opened an offer to acquire an additional 26% share in New Delhi Television (NDTV), which was positively accepted by the Indian market regulator Sebi. The deal, worth USD 60.78 million, is expected to b...

ADB and Indonesia team up on coal power plant retirement contract

ADB and Indonesia team up on coal power plant retirement contract

By Akshay Kedari

The Asian Development Bank and Indonesia, along with a private power company announced partnering to refinance and retire a coal-fired power plant under a groundbreaking carbon emissions reduction program. According to reliable sources, West Java&...